Related Experiment Video
Updated: Jul 30, 2025
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
1.9K
SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Khawaja M Talha1, Stefan D Anker2, Javed Butler1,3
1Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
International Journal of Heart Failure
|May 14, 2023
Summary
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are now recommended for heart failure (HF) across ejection fraction types. These metabolic drugs significantly reduce adverse cardiovascular outcomes, offering broad benefits beyond diabetes management.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Sodium-glucose co-transporter 2 (SGLT-2) inhibitors represent a novel therapeutic class.
- Recent trials demonstrate efficacy in heart failure (HF) across the ejection fraction spectrum.
Purpose of the Study:
- To review the evidence for SGLT-2 inhibitors in cardiovascular disease, focusing on HF.
- To discuss ongoing research into their mechanistic effects and expanded clinical applications.
Main Methods:
- Review of data from type 2 diabetes cardiovascular outcome trials.
- Analysis of primary heart failure trials investigating SGLT-2 inhibitors.
- Synthesis of current research on mechanistic pathways and future applications.
Main Results:
- SGLT-2 inhibitors significantly reduce adverse cardiovascular outcomes in patients with HF with reduced ejection fraction.
- Emerging evidence suggests benefits in HF with mildly reduced and preserved ejection fraction.
- These agents demonstrate multi-system effects, impacting HF, type 2 diabetes, and chronic kidney disease.
Conclusions:
- SGLT-2 inhibitors are integral to HF management across the ejection fraction spectrum.
- Their role is expanding due to demonstrated benefits in cardiovascular and metabolic diseases.
- Further research is exploring their mechanisms and utility in acute HF and post-myocardial infarction settings.
Related Concept Videos
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
473
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
473
01:26Heart Failure Drugs: Inotropic Agents
645
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
645
01:22Heart Failure Drugs: Diuretics
433
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
433
01:30Heart Failure IV: Classification and Diagnostic Evaluation
21
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
21
01:22Heart Failure VI: Adjunct Therapies
18
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
18